Form 4: Marimed Inc. CEO Jon Levine Reports Stock Transactions

Marimed Inc. CEO Jon Levine reports the vesting of restricted stock units and subsequent tax withholding, affecting his beneficial ownership of common stock.

Summary

• On March 7, 2025, Jon Levine, the President and CEO of Marimed Inc., reported transactions involving common stock and Restricted Stock Units (RSUs).
• 23,333 RSUs vested and converted into common stock on a one-for-one basis.
• The company withheld 8,085 shares to cover tax obligations related to the RSU vesting at a price of $0.1098 per share.
• Following these transactions, Levine directly owns 20,553,709 shares of common stock and indirectly owns 6,684,640 shares through the Jon Levine Family Trust.
• Levine disclaims beneficial ownership of the shares held in the family trust.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.

Future Outlook

The remaining RSUs will vest in two equal installments on September 7, 2025, and March 7, 2026.

Management Comments

• The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the stock ownership of key executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in the CEO's stock ownership.
• The vesting of RSUs is part of the executive compensation plan, impacting the CEO's overall remuneration.

Key Dates